Temsirolimus
- Generic Name
- Temsirolimus
- Brand Names
- Torisel
- Drug Type
- Small Molecule
- Chemical Formula
- C56H87NO16
- CAS Number
- 162635-04-3
- Unique Ingredient Identifier
- 624KN6GM2T
- Background
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
- Indication
For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
- Associated Conditions
- Advanced Renal Cell Carcinoma
- Associated Therapies
- -
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer
- Conditions
- Interventions
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
- First Posted Date
- 2011-01-24
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 40
- Registration Number
- NCT01281917
- Locations
- πΊπΈ
Bellin Memorial Hospital, Inc, Green Bay, Wisconsin, United States
πΊπΈGunderson Lutheran Health System, La Crosse, Wisconsin, United States
πΊπΈAurora Baycare Medical Center-GreenBay, Green Bay, Wisconsin, United States
Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2017-02-14
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 39
- Registration Number
- NCT01264341
- Locations
- π¬π·
Agii Anargiri Cancer Hospital, 2nd Dept of Medical Oncology, Athens, Greece
π¬π·Agii Anargiri Cancer Hospital, 3rd Dept of Medical Oncology, Athens, Greece
π¬π·Papageorgiou General Hospital, Thessaloniki, Greece
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
- Conditions
- Recurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Laryngeal Verrucous CarcinomaRecurrent Lip and Oral Cavity Squamous Cell CarcinomaRecurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult PrimaryRecurrent Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaRecurrent Nasopharyngeal Keratinizing Squamous Cell CarcinomaRecurrent Oral Cavity Verrucous CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaRecurrent Salivary Gland Carcinoma
- Interventions
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT01256385
- Locations
- πΊπΈ
Southern Illinois University School of Medicine, Springfield, Illinois, United States
πΊπΈMayo Clinic in Arizona, Scottsdale, Arizona, United States
π¨π³Chinese University of Hong Kong-Prince of Wales Hospital, Shatin, Hong Kong, China
Temsirolimus-RCC-imaging
- Conditions
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 51
- Registration Number
- NCT01246817
- Locations
- π³π±
University Medical Centre Nijmegen, Nijmegen, Gelderland, Netherlands
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 87
- Registration Number
- NCT01222715
- Locations
- πΊπΈ
New York Medical College, Valhalla, New York, United States
πΊπΈUniversity of Hawaii Cancer Center, Honolulu, Hawaii, United States
πΊπΈBlank Children's Hospital, Des Moines, Iowa, United States
Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2010-09-28
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1022
- Registration Number
- NCT01210482
- Locations
- π―π΅
Kyusyu University Hospital, Fukuoka-shi, Fukuoka PREF, Japan
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT01206140
- Locations
- πΊπΈ
City of Hope Comprehensive Cancer Center, Duarte, California, United States
πΊπΈTower Cancer Research Foundation, Beverly Hills, California, United States
πΊπΈUSC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)
- Conditions
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2016-01-27
- Target Recruit Count
- 19
- Registration Number
- NCT01206036
- Locations
- π©πͺ
CESAR Study Center, Freiburg, Germany
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2016-12-23
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT01204450
- Locations
- πΊπΈ
Carolina Healthcare System, Charlotte, North Carolina, United States
πΊπΈLineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.